alt(Okayama, 27 February) Researchers at Okayama University report in Oncotarget a promising method for targeting cancer stem cells that cause tumor growth and cancer relapse. The approach involves administering molecules that capture iron, an overload of which is known to be a potential cause of cancer.

Cancer stem cells (CSCs) are similar to normal stem cells in that they can differentiate — become cells of a specialized type. CSCs are resistant to radio- and chemotherapy and are believed to play an important role in metastasis and cancer relapse. Since iron overload is known to cause certain types of cancer, Dr. Toshiaki Ohara and Dr. Takayuki Ninomiya from Okayama University and colleagues have now tested whether the suppressing of iron levels can halt proliferation and ‘stemness’ of CSCs. The researchers found that controlled iron depletion indeed has the potential to become a therapy for targeting CSCs.

Dr. Ohara and colleagues first confirmed that in vitro, a supply of iron leads to the proliferation of CSCs, as well as the persistence of their stemness. Then, the researchers studied the effect of administering iron chelators: organic compounds that bond to particular metals, in this case iron. The scientists reckoned that through chelation, iron atoms are isolated and, potentially, ‘neutralized’. Two known iron chelators were tested: deferasirox and deferoxamine. Both compounds suppressed the proliferation of a set of mouse cancer cells. The associated fibroblasts (cells that play a key role in cancer progression and believed to originate from CSCs), however, were not affected.

Regarding the mechanism causing the suppression of CSC proliferation, Dr. Ohara and colleagues found that the iron chelators induced apoptosis (a highly regulated process leading to cell death). The scientists also studied the effect of deferasirox and deferoxamine on the CSCs’ stemness, and observed that the expression of stemness markers was suppressed — indirect evidence for stemness loss. The latter property was not observed in chemotherapy treatment, indicating the unique function of iron chelators as stemness marker suppressors. Finally, the researchers tested the effect of deferasirox and deferoxamine in vivo; both iron chelators suppressed CSC tumor growth and stemness marker expression.

The results of Dr. Ohara and colleagues show that the use of iron chelators could develop into an effective cancer treatment, complementary to standard chemotherapy. In the words of the researchers: “Although … the mechanisms [of stemness marker expression] are currently unknown … this study may represent an important first step in the development of novel iron chelation based strategies for CSC therapy.”

Cancer stem cells
A cancer stem cell (CSC) is a cancerous cell with the property of a normal stem cell that it can differentiate in various cell types found in a particular cancer sample. CSCs are tumor-forming, and cancer therapies targeting them are being developed, as CSCs are involved in cancer
metastasis and tumor relapse.
Dr. Ohara from Okayama University and colleagues have now shown that controlled iron
depletion in tumors is a promising novel strategy for targeting CSCs.

Chelation is a type of bond between metal ions and molecules or molecular ions. It involves a multiple-bonded ligand binding to the metal ion; the ligand is usually an organic compound and called a chelant or chelator.
Since iron overload in the human body can lead to the formation of free radicals, which in turn can cause cancer, Dr. Ohara and colleagues investigated whether iron depletion through chelation, using the iron chelators deferasirox and deferoxamine, can suppress the proliferation and stemness of cancer stem cells.

Iron chelators Deferasirox and Deferoxamine (DFO) suppress the expression of stemness marker. 5-FU, ordinary anti-cancer drug, did not inhibited.

Takayuki Ninomiya, Toshiaki Ohara, Kazuhiro Noma, Yuki Katsura, Ryoichi Katsube, Hajime Kashima, Takuya Kato, Yasuko Tomono, Hiroshi Tazawa, Shunsuke Kagawa, Yasuhiro Shirakawa, Fumiaki Kimura, Ling Chen, Tomonari Kasai, Masaharu Seno, Akihiro Matsukawa & Toshiyoshi Fujiwara. Iron depletion is a novel therapeutic strategy to target cancer stem cells. Oncotarget, 12 October 2017.
DOI: 10.18632/oncotarget.21846[]=21846&path[]=69293

Reference (Okayama University e-Bulletin & OU-MRU) : Assistant Professor Ohara’s team
OU-MRU Vol.22:Medical supportive device for hemodialysis catheter puncture

Correspondence to
Assistant Professor Toshiaki Ohara, M.D., Ph.D.
Department of Pathology & Experimental Medicine,
Graduate School of Medicine, Dentistry and Pharmaceutical
Sciences, Okayama University, Shikata-cho 2-5-1, Okayama
city, Okayama 700-8558, Japan
E-mail: Cette adresse email est protégée contre les robots des spammeurs, vous devez activer Javascript pour la voir.

Further information
Okayama University
1-1-1 Tsushima-naka , Kita-ku , Okayama 700-8530, Japan
Public Relations and Information Strategy
E-mail: Cette adresse email est protégée contre les robots des spammeurs, vous devez activer Javascript pour la voir.
Okayama Univ. e-Bulletin:
About Okayama University (YouTube):
Okayama University Image Movie (YouTube):

Okayama University Medical Research Updates (OU-MRU)
Vol.1:Innovative non-invasive ‘liquid biopsy’ method to capture circulating tumor cells from blood samples for genetic testing
Vol.2:Ensuring a cool recovery from cardiac arrest
Vol.3:Organ regeneration research leaps forward
Vol.4:Cardiac mechanosensitive integrator
Vol.5:Cell injections get to the heart of congenital defects
Vol.6:Fourth key molecule identified in bone development
Vol.7:Anticancer virus solution provides an alternative to surgery
Vol.8:Light-responsive dye stimulates sight in genetically blind patients
Vol.9:Diabetes drug helps towards immunity against cancer
Vol.10:Enzyme-inhibitors treat drug-resistant epilepsy
Vol.11:Compound-protein combination shows promise for arthritis treatment
Vol.12:Molecular features of the circadian clock system in fruit flies
Vol.13:Peptide directs artificial tissue growth
Vol.14:Simplified boron compound may treat brain tumours
Vol.15:Metamaterial absorbers for infrared inspection technologies
Vol.16:Epigenetics research traces how crickets restore lost limbs
Vol.17:Cell research shows pathway for suppressing hepatitis B virus
Vol.18:Therapeutic protein targets liver disease
Vol.19:Study links signalling protein to osteoarthritis
Vol.20:Lack of enzyme promotes fatty liver disease in thin patients
Vol.21:Combined gene transduction and light therapy targets gastric cancer
Vol.22:Medical supportive device for hemodialysis catheter puncture
Vol.23:Development of low cost oral inactivated vaccines for dysentery
Vol.24:Sticky molecules to tackle obesity and diabetes
Vol.25:Self-administered aroma foot massage may reduce symptoms of anxiety
Vol.26:Protein for preventing heart failure
Vol.27:Keeping cells in shape to fight sepsis
Vol.28:Viral-based therapy for bone cancer
Vol.29:Photoreactive compound allows protein synthesis control with light
Vol.30:Cancer stem cells’ role in tumor growth revealed
Vol.31:Prevention of RNA virus replication
Vol.32:Enzyme target for slowing bladder cancer invasion
Vol.33:Attacking tumors from the inside
Vol.34:Novel mouse model for studying pancreatic cancer
Vol.35:Potential cause of Lafora disease revealed
Vol.36:Overloading of protein localization triggers cellular defects
Vol.37:Protein dosage compensation mechanism unravelled
Vol.38:Bioengineered tooth restoration in a large mammal
Vol.39:Successful test of retinal prosthesis implanted in rats
Vol.40:Antibodies prolong seizure latency in epileptic mice
Vol.41:Inorganic biomaterials for soft-tissue adhesion
Vol.42:Potential drug for treating chronic pain with few side effects
Vol.43:Potential origin of cancer-associated cells revealed
Vol.44:Protection from plant extracts
Vol.45:Link between biological-clock disturbance and brain dysfunction uncovered
Vol.46:New method for suppressing lung cancer oncogene
Vol.47:Candidate genes for eye misalignment identified
Vol.48:Nanotechnology-based approach to cancer virotherapy
Vol.49:Cell membrane as material for bone formation

Okayama University (Shikata Campus, Okayama City)

Okayama University Hospital (Okayama University, Shikata Campus, Okayama City)
◆About Okayama University
Okayama University is one of the largest comprehensive universities in Japan with
roots going back to the Medical Training Place sponsored by the Lord of Okayama and
established in 1870. Now with 1,300 faculty and 13,000 students, the University offers
courses in specialties ranging from medicine and pharmacy to humanities and physical
Okayama University is located in the heart of Japan approximately 3 hours west of
Tokyo by Shinkansen.


Ajouter un Commentaire

Code de sécurité

Vitrines Sociétés

Voir toutes les vitrines